DUBLIN, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, presented the final results of a Phase 2 study of SGI-110, a novel hypomethylating agent in elderly Acute Myeloid Leukemia (AML) in an oral session on June 14 at the European Hematology Association meeting held in Milan, Italy (June 12-15).
Help employers find you! Check out all the jobs and post your resume.
